These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19280938)

  • 1. [Biological agents].
    Amano K
    Nihon Rinsho; 2009 Mar; 67(3):593-8. PubMed ID: 19280938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management for TNF failure].
    Mukai M
    Nihon Rinsho; 2007 Jul; 65(7):1299-307. PubMed ID: 17642247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CTLA4-Ig (abatacept)].
    Harigai M
    Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biologics: current therapeutic strategies for rheumatoid arthritis].
    Tanaka Y
    Nihon Rinsho; 2007 Jul; 65(7):1179-84. PubMed ID: 17642229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
    Hansen KE; Hildebrand JP; Genovese MC; Cush JJ; Patel S; Cooley DA; Cohen SB; Gangnon RE; Schiff MH
    J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept Immunex.
    Yung RL
    Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
    Reynolds J; Shojania K; Marra CA
    Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selection of one of the TNF blockers; infliximab and etanercept].
    Mimura T
    Nihon Rinsho; 2007 Jul; 65(7):1282-6. PubMed ID: 17642244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do the biologics fit into the current DMARD armamentarium?
    Kalden JR
    J Rheumatol Suppl; 2001 Jun; 62():27-35. PubMed ID: 11409155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein].
    Fujikawa K; Kawakami A; Eguchi K
    Nihon Rinsho; 2007 Jul; 65(7):1211-7. PubMed ID: 17642234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML
    Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment guidelines for the use of biologics in rheumatoid arthritis; present and future].
    Miyasaka N; Koike R
    Nihon Rinsho; 2007 Jul; 65(7):1169-78. PubMed ID: 17642228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.